St. Jude Persists In Effort To Correct The Record On Riata Study
This article was originally published in The Gray Sheet
“We will continue to work through the proper channels with the HeartRhythm journal and the Heart Rhythm Society to ensure there is an appropriate presentation of validated, accurate information,” a company spokeswoman said.
You may also be interested in...
MAUDE analysis suggests some trouble spots for St. Jude’s newer Optim-insulated ICD leads, according to researchers. But the company says the overall data shows the products to be as safe and reliable as competitors’ offerings.
St. Jude Medical reports updated Riata defibrillator lead data. Alzheimer’s RNA-based blood test studies make progress. More research news.
Brief summaries of recent medtech market and industry developments. This month we cover Covidien’s continuing buying spree, and other medtech M&A.